NCT02263989已完成1 期
Bioequivalence of the 40 mg Telmisartan Film-coated Tablet Compared With the Conventional 40 mg Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 主要终点
- Cmax (maximum measured concentration of the analyte in plasma)
研究概览
简要总结
Study to investigate the bioequivalence of the 40 mg telmisartan film-coated tablet vs. the conventional 40 mg telmisartan tablet
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 35 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males according to the following criteria:
- •Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate, body temperature), 12-lead ECG, clinical laboratory tests
- •No findings deviating from normal and of clinical relevance
- •No evidence of a clinically relevant concomitant disease
- •Age ≥20 and ≤35 years
- •Body mass index (BMI) ≥17.6 and ≤26.4 kg/m2
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
排除标准
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •Chronic or relevant acute infections
- •Any clinical relevant findings of the laboratory test deviating from normal
- •Positive result for either hepatitis B surface antigen (HBs antigen), anti hepatitis C virus (HCV) antibodies, syphilitic test or human immunodeficiency virus (HIV) test
- •History of surgery of gastrointestinal tract (except appendectomy)
- •History of relevant orthostatic hypotension (mean standing systolic blood pressure (SBP) varies by ≥20 mmHg from mean supine SBP or mean standing diastolic blood pressure (DBP) varies by ≥10 mmHg from mean supine DBP), fainting spells or blackouts
- •History of hepatic dysfunction (e.g. biliary cirrhosis, cholestasis)
- •History of serious renal dysfunction
- •History of bilateral renal artery stenosis or renal artery stenosis in a solitary kidney
- •History of cerebrovascular disorder
- •History of hyperkalemia
- •Known hypersensitivity to any component of the telmisartan formulation, or to any other angiotensin II receptor blockers (ARBs)
- •Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 7 days prior to administration or during the trial
- •Participation in another trial with an investigational drug within 4 months or 6 half-lives of the investigational drug prior to administration
- •Smoker (≥20 cigarettes/day)
- •Alcohol abuse (60 g or more ethanol/day: ex. 3 middle-sized bottles of beer, 3 gous (equivalent to 540 mL) of sake)
- •Blood donation (more than 100 mL within 4 weeks prior to administration or during the trial)
- •Excessive physical activities (within 1 week prior to administration or during the trial)
- •Intake of alcohol within 2 days prior to administration
- •Inability to comply with dietary regimen of study centre
- •Inability to refrain from smoking on trial days
研究组 & 干预措施
Telmisartan film coated tablet
Experimental
干预措施: Telmisartan film coated tablet (Drug)
Telmisartan conventional tablet
Active Comparator
干预措施: Telmisartan conventional tablet (Drug)
结局指标
主要结局
Cmax (maximum measured concentration of the analyte in plasma)
时间窗: up to 72 hours after drug administration
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to last quantifiable data point)
时间窗: up to 72 hours after drug administration
次要结局
- Number of subjects with clinically significant findings in physical examination(up to 72 hours after last administration)
- t1/2 (terminal half-life of the analyte in plasma)(up to 72 hours after drug administration)
- MRTpo (mean residence time of the analyte in the body after po administration)(up to 72 hours after drug administration)
- tmax (time from dosing to the maximum measured concentration of the analyte in plasma)(up to 72 hours after drug administration)
- Number of subjects with adverse events(up to 72 hours after last administration)
- Number of subjects with clinically significant findings in vital signs(up to 72 hours after last administration)
- Number of subjects with clinically significant findings in 12-lead electrocardiogram(up to 72 hours after last administration)
- AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(up to 72 hours after drug administration)
- λz (terminal rate constant of the analyte in plasma)(up to 72 hours after drug administration)
- Number of subjects with clinically significant findings in laboratory tests(up to 72 hours after last administration)
研究者
相似试验
已完成
1 期
Bioequivalence of Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional Telmisartan Tablet in Healthy Male VolunteersHealthyNCT02261129Boehringer Ingelheim64
已完成
1 期
Bioequivalence of Telmisartan / Ramipril Fixed Dose Combination Compared With the Monocomponents Given Concomitantly to Healthy Male and Female VolunteersHealthyNCT02214979Boehringer Ingelheim84
已完成
1 期
Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male VolunteersHealthyNCT02262598Boehringer Ingelheim30
招募中
Unknown
Bioequivalence study of Telmisartan 80 mg tabletIRCT20200105046010N77Cobel Darou Pharmaceutical Company24
已完成
1 期
Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male VolunteersHealthyNCT02259790Boehringer Ingelheim30